

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. AP32738 066876.0103	Serial No. 09/955,877
	Applicant Said I.A. SHALABY et al.	
	Filing Date September 19, 2001	Group 1654

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
PL	5 8 7 6 7 2 8	03/02/1999	Kass HD et al.			
PL	5 8 7 4 8 0 4	02/23/1999	Rogers SP			
PL	5 6 4 8 0 8 9	07/15/1997	Shawkat T			

FOREIGN PATENT DOCUMENT

Document No.	Date	Country	Class	SubClass	Translator Yes No
7 9 3 9 6 4	09/10/1999	Europe (EP)			


OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

PL	Harvard School of Public Health Jan 2004, < http://www.researchmatters.harvard.edu/story.php?article_id=673 >
↑	Buckwold, Beer, Donis, 2003 "Bovine viral diarrhea as a surrogate model of hepatitis C virus for the evaluation of anti-viral agents" Antiviral Research Vol 60(1):1-15;
	Cost of Developing a New Drug Increases to About \$1.7 Billion By PETER LANDERS , Wall Street Journal December 8, 2003 < http://online.wsj.com/article/0,,SB107083909136415400-email,00.html >
	Abramowicz M, ed., "Enfuvirtide (Fuzeon) for HIV Infection" Med Lett Drugs Ther. 2003 Jun 23; 45(1159): 49-50;
↓	El-Awady, et al., Clinica Chimica Acta, 283(1-2):1-14 (1999);
PL	McHutchison et al., "Interferon Alpha-2b Alone or in Combination with Ribavirin as Initial Treatment fro Chronic Hepatitis C", New England Journal of Medicine Vol 339 Number 21 November 19, 1998, 1485-1492;

NY02:472768.1

Examiner 	Date Considered 10/01/04
--------------	-----------------------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



Substitute

Page 2 of 3

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark OfficeAtty. Docket No.
AP32738 066876.0103Serial No.
09/955,877**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Said I.A. SHALABY et al.Filing Date
September 19, 2001Group
1654

Yokozawa, et al., J. Traditional Medicine, 15(1):45-51 (1998)

Alter, M.J., Hepatology, 26(1):62S-65S (1997)

Alam, et al., Phytotherapy Research, 10(1):58-61 (1996);

D.S. Chen, J. Formos. Med. Assoc., 95(1):6-12 (1996);

Detre, et al., Viral Hepatitis Rev., 2:219-228 (1996);

D.C. Dale and D.D. Federman, eds., Sci. Amer. Medicine, New York, 4(8):1-10 (1996);

Hibbs, et al., J. Infect. Dis. 168:789-790 (1993);

Lok, et al., Gastroenterology, 105(6):1833-1838 (1993);

Flint SJ et al., Principles of Virology: Molecular Biology, Pathogenesis, and Control, ASM Press, Washington DC, 1990, p.691;

Medicinal Plants of North Africa, Loutfy Boulos, Reference Publications, Inc., pp.150-51 (1983);

Medicinal Plants of North Africa, pp. 74-75, 92-93 (1983);

Bergmeyer and Horder, Clinica Chemica Acta 105:147f-154f (1980);

Encyclopedia of Common Natural Ingredients, Used in Food, Drugs, and Cosmetics, John Wiley & Sons, New York, p.169 (1980);

International Federation of Clinical Chemistry, Scientific Committee, J. Clin. Chem. Clin. Biochem., 18:521-534 (1980);

NY02:472768.1

Examiner

Date Considered

10/01/04

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

